Bausch + Lomb Corporation (BLCO) 10-Year Financial Performance & Capital Metrics

BLCO • • Industrial / General

HealthcareMedical InstrumentsOphthalmic Devices & Vision CareContact Lenses & Vision Correction

AboutBausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.Show more

Revenue $4.79B +15.6%
EBITDA $598M +16.8%
Net Income -$317M -21.9%
EPS (Diluted) -0.90 -21.6%
Gross Margin 60.93% +0.9%
EBITDA Margin 12.48% +1.1%
Operating Margin 3.38% +7.8%
Net Margin -6.62% -5.5%
ROE -4.71% -27.0%
ROIC 1.08% +14.1%
Debt/Equity 0.75 +11.6%
Interest Coverage 0.41 -11.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading near 52-week high
✓Trading at only 0.9x book value

✗Weaknesses

✗Negative free cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y4.87%

3Y8.36%

TTM6.23%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM17.12%

EPS CAGR

10Y-

5Y-

3Y-

TTM17.18%

ROCE

10Y Avg2.38%

5Y Avg2.09%

3Y Avg1.56%

Latest1.37%

Peer Comparison

Contact Lenses & Vision Correction

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
COOThe Cooper Companies, Inc.	16.13B	82.31	44.02	5.06%	10.08%	4.88%	2.69%	0.34
LUCYInnovative Eyewear, Inc.	8.19M	1.53	-0.29	41.99%	-770.01%	-17.97%
BLCOBausch + Lomb Corporation	6.18B	17.44	-19.38	15.56%	-6.13%	-4.69%		0.75
STAASTAAR Surgical Company	1.04B	20.97	-51.15	-2.64%	-41.79%	-27.24%		0.10
WRBYWarby Parker Inc.	3B	28.33	-166.65	15.16%	0.08%	0.19%	1.16%	0.66

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	3.78B	3.41B	3.77B	3.77B	4.15B	4.79B
Revenue Growth %	-	-0.1%	0.1%	0%	0.1%	0.16%
Cost of Goods Sold+	1.33B	1.28B	1.47B	1.52B	1.64B	1.87B
COGS % of Revenue	0.35%	0.38%	0.39%	0.4%	0.4%	0.39%
Gross Profit+	2.45B	2.13B	2.3B	2.25B	2.5B	2.92B
Gross Margin %	0.65%	0.62%	0.61%	0.6%	0.6%	0.61%
Gross Profit Growth %	-	-0.13%	0.08%	-0.02%	0.11%	0.17%
Operating Expenses+	2.06B	1.87B	1.97B	2.04B	2.37B	2.76B
OpEx % of Revenue	0.54%	0.55%	0.52%	0.54%	0.57%	0.58%
Selling, General & Admin	1.38B	1.25B	1.39B	1.48B	1.74B	2.08B
SG&A % of Revenue	0.37%	0.37%	0.37%	0.39%	0.42%	0.43%
Research & Development	258M	281M	271M	307M	324M	343M
R&D % of Revenue	0.07%	0.08%	0.07%	0.08%	0.08%	0.07%
Other Operating Expenses	415M	333M	309M	257M	314M	332M
Operating Income+	396M	260M	329M	207M	130M	162M
Operating Margin %	0.1%	0.08%	0.09%	0.05%	0.03%	0.03%
Operating Income Growth %	-	-0.34%	0.27%	-0.37%	-0.37%	0.25%
EBITDA+	865M	702M	744M	586M	512M	598M
EBITDA Margin %	0.23%	0.21%	0.2%	0.16%	0.12%	0.12%
EBITDA Growth %	-	-0.19%	0.06%	-0.21%	-0.13%	0.17%
D&A (Non-Cash Add-back)	469M	442M	415M	379M	382M	436M
EBIT	467M	290M	318M	219M	117M	165M
Net Interest Income+	1M	3M	0	-140M	-268M	-384M
Interest Income	1M	3M	0	6M	15M	15M
Interest Expense	0	0	0	146M	283M	399M
Other Income/Expense	3M	30M	-11M	-134M	-296M	-396M
Pretax Income+	399M	290M	318M	73M	-166M	-234M
Pretax Margin %	0.11%	0.08%	0.08%	0.02%	-0.04%	-0.05%
Income Tax+	96M	307M	125M	58M	82M	71M
Effective Tax Rate %	0.75%	-0.06%	0.57%	0.08%	1.57%	1.35%
Net Income+	298M	-18M	182M	6M	-260M	-317M
Net Margin %	0.08%	-0.01%	0.05%	0%	-0.06%	-0.07%
Net Income Growth %	-	-1.06%	11.11%	-0.97%	-44.33%	-0.22%
Net Income (Continuing)	303M	-17M	193M	15M	-248M	-305M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	73M	70M	73M	68M	70M	71M
EPS (Diluted)+	0.85	-0.05	0.52	0.04	-0.74	-0.90
EPS Growth %	-	-1.06%	11.7%	-0.92%	-18.25%	-0.22%
EPS (Basic)	0.85	-0.05	0.52	0.04	-0.74	-0.90
Diluted Shares Outstanding	350M	350M	350M	350M	350.5M	351.8M
Basic Shares Outstanding	350M	350M	350M	350M	350.5M	351.8M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.7B	1.65B	1.64B	2.14B	2.74B	2.79B
Cash & Short-Term Investments	192M	238M	174M	380M	334M	305M
Cash Only	192M	238M	174M	380M	334M	305M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	713M	645M	721M	726M	875M	1.03B
Days Sales Outstanding	68.88	69	69.9	70.33	77.03	78.17
Inventory	592M	616M	572M	628M	1.03B	1.04B
Days Inventory Outstanding	162.83	174.97	142.32	150.9	228.51	202
Other Current Assets	198M	155M	3M	403M	505M	421M
Total Non-Current Assets+	9.77B	9.61B	9.19B	9.01B	10.7B	10.68B
Property, Plant & Equipment	1.09B	1.26B	1.34B	1.42B	1.5B	1.49B
Fixed Asset Turnover	3.47x	2.70x	2.82x	2.66x	2.76x	3.23x
Goodwill	4.55B	4.68B	4.59B	4.51B	4.58B	4.52B
Intangible Assets	2.85B	2.56B	2.26B	2.06B	3.59B	3.49B
Long-Term Investments	0	0	0	12M	19M	19M
Other Non-Current Assets	82M	65M	1B	84M	92M	275M
Total Assets+	11.47B	11.27B	10.82B	11.14B	13.44B	13.47B
Asset Turnover	0.33x	0.30x	0.35x	0.34x	0.31x	0.36x
Asset Growth %	-	-0.02%	-0.04%	0.03%	0.21%	0%
Total Current Liabilities+	1.03B	909M	1.1B	1.3B	1.58B	1.74B
Accounts Payable	262M	178M	239M	317M	522M	389M
Days Payables Outstanding	72.06	50.56	59.46	76.17	116.04	75.85
Short-Term Debt	16M	18M	28M	51M	57M	40M
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	573M	544M	356M	732M	709M	1.28B
Current Ratio	1.64x	1.82x	1.49x	1.65x	1.74x	1.60x
Quick Ratio	1.07x	1.14x	0.97x	1.16x	1.09x	1.01x
Cash Conversion Cycle	159.65	193.41	152.75	145.06	189.51	204.32
Total Non-Current Liabilities+	401M	369M	322M	2.75B	4.94B	5.19B
Long-Term Debt	0	0	0	2.41B	4.53B	4.74B
Capital Lease Obligations	77M	83M	92M	92M	87M	120M
Deferred Tax Liabilities	0	0	0	7M	14M	13M
Other Non-Current Liabilities	324M	286M	230M	237M	310M	310M
Total Liabilities	1.44B	1.28B	1.42B	4.04B	6.52B	6.92B
Total Debt+	93M	101M	140M	2.55B	4.68B	4.94B
Net Debt	-99M	-137M	-34M	2.17B	4.34B	4.63B
Debt / Equity	0.01x	0.01x	0.01x	0.36x	0.68x	0.75x
Debt / EBITDA	0.11x	0.14x	0.19x	4.36x	9.13x	8.25x
Net Debt / EBITDA	-0.11x	-0.20x	-0.05x	3.71x	8.48x	7.74x
Interest Coverage	-	-	-	1.42x	0.46x	0.41x
Total Equity+	10.03B	9.99B	9.4B	7.1B	6.92B	6.54B
Equity Growth %	-	-0%	-0.06%	-0.24%	-0.03%	-0.05%
Book Value per Share	28.66	28.54	26.86	20.29	19.74	18.60
Total Shareholders' Equity	9.96B	9.92B	9.33B	7.03B	6.85B	6.47B
Common Stock	11.01B	10.81B	10.36B	0	0	0
Retained Earnings	0	0	0	6M	-254M	-571M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	-1.05B	-889M	-1.03B	-1.26B	-1.25B	-1.39B
Minority Interest	73M	70M	73M	68M	70M	71M

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	799M	522M	873M	345M	-17M	232M
Operating CF Margin %	0.21%	0.15%	0.23%	0.09%	-0%	0.05%
Operating CF Growth %	-	-0.35%	0.67%	-0.6%	-1.05%	14.65%
Net Income	303M	-17M	193M	15M	-248M	-305M
Depreciation & Amortization	469M	442M	415M	379M	382M	436M
Stock-Based Compensation	50M	50M	62M	62M	74M	92M
Deferred Taxes	-39M	97M	116M	-90M	-10M	-10M
Other Non-Cash Items	56M	9M	59M	-2M	72M	106M
Working Capital Changes	-40M	-59M	28M	-19M	-287M	-87M
Change in Receivables	-21M	77M	-107M	-95M	-121M	-227M
Change in Inventory	-91M	-32M	-15M	-106M	-264M	-147M
Change in Payables	78M	-144M	163M	189M	245M	126M
Cash from Investing+	-186M	-256M	-214M	-215M	-2.11B	-412M
Capital Expenditures	-180M	-259M	-193M	-175M	-181M	-291M
CapEx % of Revenue	0.05%	0.08%	0.05%	0.05%	0.04%	0.06%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	-6M	-6M	0	-45M	14M	-123M
Cash from Financing+	-606M	-232M	-712M	81M	2.08B	178M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	-606M	-232M	-740M	-2.38B	-37M	-11M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	619M	263M	680M	170M	-198M	-59M
FCF Margin %	0.16%	0.08%	0.18%	0.05%	-0.05%	-0.01%
FCF Growth %	-	-0.58%	1.59%	-0.75%	-2.16%	0.7%
FCF per Share	1.77	0.75	1.94	0.49	-0.56	-0.17
FCF Conversion (FCF/Net Income)	2.68x	-29.00x	4.80x	57.50x	0.07x	-0.73x
Interest Paid	0	3M	0	132M	238M	415M
Taxes Paid	0	57M	53M	83M	64M	91M

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	2.97%	-0.18%	1.88%	0.07%	-3.71%	-4.71%
Return on Invested Capital (ROIC)	2.99%	1.97%	2.57%	1.67%	0.95%	1.08%
Gross Margin	64.88%	62.34%	61.04%	59.69%	60.4%	60.93%
Net Margin	7.89%	-0.53%	4.83%	0.16%	-6.27%	-6.62%
Debt / Equity	0.01x	0.01x	0.01x	0.36x	0.68x	0.75x
Interest Coverage	-	-	-	1.42x	0.46x	0.41x
FCF Conversion	2.68x	-29.00x	4.80x	57.50x	0.07x	-0.73x
Revenue Growth	-	-9.69%	10.35%	0.08%	10.03%	15.56%

Revenue by Segment

	2022	2023	2024
Device Products	-	1.65B	1.8B
Device Products Growth	-	-	9.09%
Over the Counter Products	-	1.61B	1.72B
Over the Counter Products Growth	-	-	7.01%
Pharmaceutical Products	-	618M	969M
Pharmaceutical Products Growth	-	-	56.80%
Branded and Other Generic Products	-	252M	281M
Branded and Other Generic Products Growth	-	-	11.51%
Other Revenues	-	15M	17M
Other Revenues Growth	-	-	13.33%
Product	3.75B	-	-
Product Growth	-	-	-
Product and Service, Other	22M	-	-
Product and Service, Other Growth	-	-	-

Revenue by Geography

	2022	2023	2024
United States and Puerto Rico	1.7B	1.93B	2.41B
United States and Puerto Rico Growth	-	14.10%	24.77%
Other Countries	572M	655M	759M
Other Countries Growth	-	14.51%	15.88%
CHINA	343M	344M	358M
CHINA Growth	-	0.29%	4.07%
FRANCE	195M	210M	227M
FRANCE Growth	-	7.69%	8.10%
JAPAN	192M	187M	180M
JAPAN Growth	-	-2.60%	-3.74%
GERMANY	138M	147M	152M
GERMANY Growth	-	6.52%	3.40%
CANADA	101M	110M	127M
CANADA Growth	-	8.91%	15.45%
SPAIN	77M	85M	92M
SPAIN Growth	-	10.39%	8.24%
ITALY	72M	82M	91M
ITALY Growth	-	13.89%	10.98%
MEXICO	55M	68M	75M
MEXICO Growth	-	23.64%	10.29%
POLAND	44M	51M	65M
POLAND Growth	-	15.91%	27.45%
KOREA, REPUBLIC OF	44M	46M	-
KOREA, REPUBLIC OF Growth	-	4.55%	-

Frequently Asked Questions

Growth & Financials

Bausch + Lomb Corporation (BLCO) reported $4.98B in revenue for fiscal year 2024. This represents a 32% increase from $3.78B in 2019.

Bausch + Lomb Corporation (BLCO) grew revenue by 15.6% over the past year. This is strong growth.

Bausch + Lomb Corporation (BLCO) reported a net loss of $305.0M for fiscal year 2024.

Dividend & Returns

Bausch + Lomb Corporation (BLCO) has a return on equity (ROE) of -4.7%. Negative ROE indicates the company is unprofitable.

Bausch + Lomb Corporation (BLCO) had negative free cash flow of $194.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Bausch + Lomb Corporation (BLCO) 10-Year Financial Performance & Capital Metrics

BLCO • • Industrial / General

HealthcareMedical InstrumentsOphthalmic Devices & Vision CareContact Lenses & Vision Correction

Revenue $4.79B +15.6%
EBITDA $598M +16.8%
Net Income -$317M -21.9%
EPS (Diluted) -0.90 -21.6%
Gross Margin 60.93% +0.9%
EBITDA Margin 12.48% +1.1%
Operating Margin 3.38% +7.8%
Net Margin -6.62% -5.5%
ROE -4.71% -27.0%
ROIC 1.08% +14.1%
Debt/Equity 0.75 +11.6%
Interest Coverage 0.41 -11.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading near 52-week high
✓Trading at only 0.9x book value

✗Weaknesses

✗Negative free cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y4.87%

3Y8.36%

TTM6.23%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM17.12%

EPS CAGR

10Y-

5Y-

3Y-

TTM17.18%

ROCE

10Y Avg2.38%

5Y Avg2.09%

3Y Avg1.56%

Latest1.37%

Peer Comparison

Contact Lenses & Vision Correction

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
COOThe Cooper Companies, Inc.	16.13B	82.31	44.02	5.06%	10.08%	4.88%	2.69%	0.34
LUCYInnovative Eyewear, Inc.	8.19M	1.53	-0.29	41.99%	-770.01%	-17.97%
BLCOBausch + Lomb Corporation	6.18B	17.44	-19.38	15.56%	-6.13%	-4.69%		0.75
STAASTAAR Surgical Company	1.04B	20.97	-51.15	-2.64%	-41.79%	-27.24%		0.10
WRBYWarby Parker Inc.	3B	28.33	-166.65	15.16%	0.08%	0.19%	1.16%	0.66

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	3.78B	3.41B	3.77B	3.77B	4.15B	4.79B
Revenue Growth %	-	-0.1%	0.1%	0%	0.1%	0.16%
Cost of Goods Sold+	1.33B	1.28B	1.47B	1.52B	1.64B	1.87B
COGS % of Revenue	0.35%	0.38%	0.39%	0.4%	0.4%	0.39%
Gross Profit+	2.45B	2.13B	2.3B	2.25B	2.5B	2.92B
Gross Margin %	0.65%	0.62%	0.61%	0.6%	0.6%	0.61%
Gross Profit Growth %	-	-0.13%	0.08%	-0.02%	0.11%	0.17%
Operating Expenses+	2.06B	1.87B	1.97B	2.04B	2.37B	2.76B
OpEx % of Revenue	0.54%	0.55%	0.52%	0.54%	0.57%	0.58%
Selling, General & Admin	1.38B	1.25B	1.39B	1.48B	1.74B	2.08B
SG&A % of Revenue	0.37%	0.37%	0.37%	0.39%	0.42%	0.43%
Research & Development	258M	281M	271M	307M	324M	343M
R&D % of Revenue	0.07%	0.08%	0.07%	0.08%	0.08%	0.07%
Other Operating Expenses	415M	333M	309M	257M	314M	332M
Operating Income+	396M	260M	329M	207M	130M	162M
Operating Margin %	0.1%	0.08%	0.09%	0.05%	0.03%	0.03%
Operating Income Growth %	-	-0.34%	0.27%	-0.37%	-0.37%	0.25%
EBITDA+	865M	702M	744M	586M	512M	598M
EBITDA Margin %	0.23%	0.21%	0.2%	0.16%	0.12%	0.12%
EBITDA Growth %	-	-0.19%	0.06%	-0.21%	-0.13%	0.17%
D&A (Non-Cash Add-back)	469M	442M	415M	379M	382M	436M
EBIT	467M	290M	318M	219M	117M	165M
Net Interest Income+	1M	3M	0	-140M	-268M	-384M
Interest Income	1M	3M	0	6M	15M	15M
Interest Expense	0	0	0	146M	283M	399M
Other Income/Expense	3M	30M	-11M	-134M	-296M	-396M
Pretax Income+	399M	290M	318M	73M	-166M	-234M
Pretax Margin %	0.11%	0.08%	0.08%	0.02%	-0.04%	-0.05%
Income Tax+	96M	307M	125M	58M	82M	71M
Effective Tax Rate %	0.75%	-0.06%	0.57%	0.08%	1.57%	1.35%
Net Income+	298M	-18M	182M	6M	-260M	-317M
Net Margin %	0.08%	-0.01%	0.05%	0%	-0.06%	-0.07%
Net Income Growth %	-	-1.06%	11.11%	-0.97%	-44.33%	-0.22%
Net Income (Continuing)	303M	-17M	193M	15M	-248M	-305M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	73M	70M	73M	68M	70M	71M
EPS (Diluted)+	0.85	-0.05	0.52	0.04	-0.74	-0.90
EPS Growth %	-	-1.06%	11.7%	-0.92%	-18.25%	-0.22%
EPS (Basic)	0.85	-0.05	0.52	0.04	-0.74	-0.90
Diluted Shares Outstanding	350M	350M	350M	350M	350.5M	351.8M
Basic Shares Outstanding	350M	350M	350M	350M	350.5M	351.8M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.7B	1.65B	1.64B	2.14B	2.74B	2.79B
Cash & Short-Term Investments	192M	238M	174M	380M	334M	305M
Cash Only	192M	238M	174M	380M	334M	305M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	713M	645M	721M	726M	875M	1.03B
Days Sales Outstanding	68.88	69	69.9	70.33	77.03	78.17
Inventory	592M	616M	572M	628M	1.03B	1.04B
Days Inventory Outstanding	162.83	174.97	142.32	150.9	228.51	202
Other Current Assets	198M	155M	3M	403M	505M	421M
Total Non-Current Assets+	9.77B	9.61B	9.19B	9.01B	10.7B	10.68B
Property, Plant & Equipment	1.09B	1.26B	1.34B	1.42B	1.5B	1.49B
Fixed Asset Turnover	3.47x	2.70x	2.82x	2.66x	2.76x	3.23x
Goodwill	4.55B	4.68B	4.59B	4.51B	4.58B	4.52B
Intangible Assets	2.85B	2.56B	2.26B	2.06B	3.59B	3.49B
Long-Term Investments	0	0	0	12M	19M	19M
Other Non-Current Assets	82M	65M	1B	84M	92M	275M
Total Assets+	11.47B	11.27B	10.82B	11.14B	13.44B	13.47B
Asset Turnover	0.33x	0.30x	0.35x	0.34x	0.31x	0.36x
Asset Growth %	-	-0.02%	-0.04%	0.03%	0.21%	0%
Total Current Liabilities+	1.03B	909M	1.1B	1.3B	1.58B	1.74B
Accounts Payable	262M	178M	239M	317M	522M	389M
Days Payables Outstanding	72.06	50.56	59.46	76.17	116.04	75.85
Short-Term Debt	16M	18M	28M	51M	57M	40M
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	573M	544M	356M	732M	709M	1.28B
Current Ratio	1.64x	1.82x	1.49x	1.65x	1.74x	1.60x
Quick Ratio	1.07x	1.14x	0.97x	1.16x	1.09x	1.01x
Cash Conversion Cycle	159.65	193.41	152.75	145.06	189.51	204.32
Total Non-Current Liabilities+	401M	369M	322M	2.75B	4.94B	5.19B
Long-Term Debt	0	0	0	2.41B	4.53B	4.74B
Capital Lease Obligations	77M	83M	92M	92M	87M	120M
Deferred Tax Liabilities	0	0	0	7M	14M	13M
Other Non-Current Liabilities	324M	286M	230M	237M	310M	310M
Total Liabilities	1.44B	1.28B	1.42B	4.04B	6.52B	6.92B
Total Debt+	93M	101M	140M	2.55B	4.68B	4.94B
Net Debt	-99M	-137M	-34M	2.17B	4.34B	4.63B
Debt / Equity	0.01x	0.01x	0.01x	0.36x	0.68x	0.75x
Debt / EBITDA	0.11x	0.14x	0.19x	4.36x	9.13x	8.25x
Net Debt / EBITDA	-0.11x	-0.20x	-0.05x	3.71x	8.48x	7.74x
Interest Coverage	-	-	-	1.42x	0.46x	0.41x
Total Equity+	10.03B	9.99B	9.4B	7.1B	6.92B	6.54B
Equity Growth %	-	-0%	-0.06%	-0.24%	-0.03%	-0.05%
Book Value per Share	28.66	28.54	26.86	20.29	19.74	18.60
Total Shareholders' Equity	9.96B	9.92B	9.33B	7.03B	6.85B	6.47B
Common Stock	11.01B	10.81B	10.36B	0	0	0
Retained Earnings	0	0	0	6M	-254M	-571M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	-1.05B	-889M	-1.03B	-1.26B	-1.25B	-1.39B
Minority Interest	73M	70M	73M	68M	70M	71M

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	799M	522M	873M	345M	-17M	232M
Operating CF Margin %	0.21%	0.15%	0.23%	0.09%	-0%	0.05%
Operating CF Growth %	-	-0.35%	0.67%	-0.6%	-1.05%	14.65%
Net Income	303M	-17M	193M	15M	-248M	-305M
Depreciation & Amortization	469M	442M	415M	379M	382M	436M
Stock-Based Compensation	50M	50M	62M	62M	74M	92M
Deferred Taxes	-39M	97M	116M	-90M	-10M	-10M
Other Non-Cash Items	56M	9M	59M	-2M	72M	106M
Working Capital Changes	-40M	-59M	28M	-19M	-287M	-87M
Change in Receivables	-21M	77M	-107M	-95M	-121M	-227M
Change in Inventory	-91M	-32M	-15M	-106M	-264M	-147M
Change in Payables	78M	-144M	163M	189M	245M	126M
Cash from Investing+	-186M	-256M	-214M	-215M	-2.11B	-412M
Capital Expenditures	-180M	-259M	-193M	-175M	-181M	-291M
CapEx % of Revenue	0.05%	0.08%	0.05%	0.05%	0.04%	0.06%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	-6M	-6M	0	-45M	14M	-123M
Cash from Financing+	-606M	-232M	-712M	81M	2.08B	178M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	-606M	-232M	-740M	-2.38B	-37M	-11M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	619M	263M	680M	170M	-198M	-59M
FCF Margin %	0.16%	0.08%	0.18%	0.05%	-0.05%	-0.01%
FCF Growth %	-	-0.58%	1.59%	-0.75%	-2.16%	0.7%
FCF per Share	1.77	0.75	1.94	0.49	-0.56	-0.17
FCF Conversion (FCF/Net Income)	2.68x	-29.00x	4.80x	57.50x	0.07x	-0.73x
Interest Paid	0	3M	0	132M	238M	415M
Taxes Paid	0	57M	53M	83M	64M	91M

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	2.97%	-0.18%	1.88%	0.07%	-3.71%	-4.71%
Return on Invested Capital (ROIC)	2.99%	1.97%	2.57%	1.67%	0.95%	1.08%
Gross Margin	64.88%	62.34%	61.04%	59.69%	60.4%	60.93%
Net Margin	7.89%	-0.53%	4.83%	0.16%	-6.27%	-6.62%
Debt / Equity	0.01x	0.01x	0.01x	0.36x	0.68x	0.75x
Interest Coverage	-	-	-	1.42x	0.46x	0.41x
FCF Conversion	2.68x	-29.00x	4.80x	57.50x	0.07x	-0.73x
Revenue Growth	-	-9.69%	10.35%	0.08%	10.03%	15.56%

Revenue by Segment

	2022	2023	2024
Device Products	-	1.65B	1.8B
Device Products Growth	-	-	9.09%
Over the Counter Products	-	1.61B	1.72B
Over the Counter Products Growth	-	-	7.01%
Pharmaceutical Products	-	618M	969M
Pharmaceutical Products Growth	-	-	56.80%
Branded and Other Generic Products	-	252M	281M
Branded and Other Generic Products Growth	-	-	11.51%
Other Revenues	-	15M	17M
Other Revenues Growth	-	-	13.33%
Product	3.75B	-	-
Product Growth	-	-	-
Product and Service, Other	22M	-	-
Product and Service, Other Growth	-	-	-

Revenue by Geography

	2022	2023	2024
United States and Puerto Rico	1.7B	1.93B	2.41B
United States and Puerto Rico Growth	-	14.10%	24.77%
Other Countries	572M	655M	759M
Other Countries Growth	-	14.51%	15.88%
CHINA	343M	344M	358M
CHINA Growth	-	0.29%	4.07%
FRANCE	195M	210M	227M
FRANCE Growth	-	7.69%	8.10%
JAPAN	192M	187M	180M
JAPAN Growth	-	-2.60%	-3.74%
GERMANY	138M	147M	152M
GERMANY Growth	-	6.52%	3.40%
CANADA	101M	110M	127M
CANADA Growth	-	8.91%	15.45%
SPAIN	77M	85M	92M
SPAIN Growth	-	10.39%	8.24%
ITALY	72M	82M	91M
ITALY Growth	-	13.89%	10.98%
MEXICO	55M	68M	75M
MEXICO Growth	-	23.64%	10.29%
POLAND	44M	51M	65M
POLAND Growth	-	15.91%	27.45%
KOREA, REPUBLIC OF	44M	46M	-
KOREA, REPUBLIC OF Growth	-	4.55%	-

Frequently Asked Questions

Growth & Financials

Bausch + Lomb Corporation (BLCO) reported $4.98B in revenue for fiscal year 2024. This represents a 32% increase from $3.78B in 2019.

Bausch + Lomb Corporation (BLCO) grew revenue by 15.6% over the past year. This is strong growth.

Bausch + Lomb Corporation (BLCO) reported a net loss of $305.0M for fiscal year 2024.

Dividend & Returns

Bausch + Lomb Corporation (BLCO) has a return on equity (ROE) of -4.7%. Negative ROE indicates the company is unprofitable.

Bausch + Lomb Corporation (BLCO) had negative free cash flow of $194.5M in fiscal year 2024, likely due to heavy capital investments.